Targeted Therapy for Biliary Tract Cancer
AbstractIt is necessary to establish effective chemotherapy to improve the survival of patients with biliary tract cancer, because most of these patients are unsuitable candidates for surgery, and even patients undergoing curative surgery often have recurrence. Recently, the combination of cisplatin plus gemcitabine was reported to show survival benefits over gemcitabine alone in randomized clinical trials conducted in the United Kingdom and Japan. Thus, the combination of cisplatin plus gemcitabine is now recognized as the standard therapy for unresectable biliary tract cancer. One of the next issues that need to be addressed is whether molecular targeted agents might also be effective against biliary tract cancer. Although some targeted agents have been investigated as monotherapy for first-line chemotherapy, none were found to exert satisfactory efficacy. On the other hand, monoclonal antibodies such as bevacizumab and cetuximab have also been investigated in combination with a gemcitabine-based regimen and have been demonstrated to show promising activity. Furthermore, clinical trials using new targeted agents for biliary tract cancer are also proposed. This cancer is a relatively rare and heterogeneous tumor consisting of cholangiocarcinoma and gallbladder carcinoma. Therefore, a large randomized clinical trial is necessary to confirm the efficacy of chemotherapy, and international collaboration is important. View Full-Text
Share & Cite This Article
Furuse, J.; Okusaka, T. Targeted Therapy for Biliary Tract Cancer. Cancers 2011, 3, 2243-2254.
Furuse J, Okusaka T. Targeted Therapy for Biliary Tract Cancer. Cancers. 2011; 3(2):2243-2254.Chicago/Turabian Style
Furuse, Junji; Okusaka, Takuji. 2011. "Targeted Therapy for Biliary Tract Cancer." Cancers 3, no. 2: 2243-2254.